Ipsen quietly returns cancer drug IPN01194 to AGV Discovery

Why it matters: The decision removes one of Ipsen’s two experimental MAPK-pathway inhibitors for solid tumours and returns a clinical-stage programme to the small French biotech that discovered it.

• “Upon thorough scientific review, we have concluded that IPN01194 no longer holds this transformational potential we are striving for,” Ipsen told European Biotechnology. “Therefore, Ipsen has taken the decision not to continue development of the program and return the rights to AGV Discovery.”

Zoom in: IPN01194 is an oral small molecule designed to inhibit ERK1 and ERK2, the final kinases in the MAPK/ERK signalling cascade. Ipsen was testing the drug in patients with advanced solid tumours carrying MAPK-pathway alterations, including metastatic melanoma, colorectal cancer, pancreatic adenocarcinoma and head and neck cancer.

• The first-in-human study began in April 2024 and originally aimed to enrol 220 participants. Its current registry entry lists 36 participants and describes the trial as active but no longer recruiting, indicating that the planned Phase IIa expansion did not proceed.
• Ipsen has not publicly disclosed clinical results from the study or said whether the decision was driven by efficacy, safety, pharmacokinetics or another aspect of the programme.
• The financial impact is also unclear. Ipsen’s half-year report records the derecognition of €15.6m in intangible assets following the termination of studies, but does not identify the affected programmes.

Backstory: Montpellier-based AGV Discovery began working with Ipsen under a research collaboration and option agreement in September 2020. Ipsen exercised its option and acquired exclusive worldwide rights to IPN01194 in August 2022 after the programme met an undisclosed preclinical milestone.

• AGV describes its ERK inhibitor programme as its “first major success”. Its pipeline contains three projects, two of which remain at an early stage in oncology.

What’s next: When asked to comment on Ipsen’s email, Cédric Bories, AGV’s president, said, “We continue to view AGV1805 as a valuable clinical-stage asset, supported by a strong preclinical package and encouraging clinical development experience. The rights reversion enables us to pursue a focused development strategy aimed at maximizing the program’s potential, and we are open to partnering opportunities, particularly in combination approaches where ERK inhibition may offer significant therapeutic value.” The company is now actively engaging with potential partners and investors to advance the program.

The big picture: Ipsen is narrowing rather than abandoning its work on the MAPK pathway, a signalling cascade that regulates cell proliferation and survival but is frequently overactivated by cancer-driving mutations. Its remaining MAPK portfolio includes:

• IPN01195: A pan-RAF inhibitor targeting several RAF proteins, including their dimeric forms. The programme came from a collaboration with IRICoR and Université de Montréal and entered a recruiting Phase 1 trial in 2025. The 85-participant study is enrolling patients with advanced solid tumours carrying alterations in BRAF, ARAF, RAF1, HRAS, KRAS or NRAS.
• Ipsen also expanded its collaboration with IRICoR and Université de Montréal in December 2025, adding two undisclosed research programmes targeting pathways complementary to MAPK signalling.
• Ipsen also holds a license from Day One Biopharmaceuticals outside the US to Ojemda (tovorafenib), a type II RAF inhibitor. It received conditional EU approval in April 2026 for children with previously treated, BRAF-altered low-grade glioma.

What we’re watching: IPN01195 now becomes Ipsen’s main experimental MAPK inhibitor for adult solid tumours. Early clinical data will show whether targeting RAF more broadly can succeed where the downstream ERK programme failed to meet Ipsen’s development threshold.

The bottom line: Ipsen still sees MAPK signalling as an important oncology strategy, but IPN01194 now returns to AGV with an uncertain future and without public data explaining why its original partner walked away.